Claims for Patent: 10,183,012
✉ Email this page to a colleague
Summary for Patent: 10,183,012
| Title: | Compounds and compositions and methods of use |
| Abstract: | Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. |
| Inventor(s): | Quart; Barry D. (Encinitas, CA), Girardet; Jean-Luc (San Diego, CA), Gunic; Esmir (San Diego, CA), Yeh; Li-Tain (Irvine, CA) |
| Assignee: | Ardea Biosciences, Inc. (San Diego, CA) |
| Application Number: | 15/358,586 |
| Patent Claims: |
1. A method of treating hyperuricemia associated with gout in a human, the method comprising administering to the human a compound of formula (IV): ##STR00178## or a
pharmaceutically acceptable salt, ester, or tautomer thereof.
2. The method of claim 1, wherein the pharmaceutically acceptable salt is administered to the human, and wherein the pharmaceutically acceptable salt is an ammonium, a primary amine, a secondary amine, a tertiary amine, a lithium, a sodium, a potassium, a calcium, a magnesium, or an aluminum salt. 3. The method of claim 2, wherein the pharmaceutically acceptable salt is a sodium salt. 4. The method of claim 1, wherein said administering is orally. 5. The method of claim 1, wherein said compound is administered in combination with a pharmaceutically acceptable carrier, excipient, or diluent, in a pharmaceutical composition. 6. The method of claim 5, wherein the pharmaceutical composition is a tablet or capsule. 7. The method of claim 5, wherein the pharmaceutical composition is a tablet. 8. The method of claim 7, wherein the pharmaceutical composition is a coated tablet. 9. The method of claim 7, wherein the tablet comprises lactose. 10. The method of claim 7, wherein the tablet comprises microcrystalline cellulose. 11. The method of claim 7, wherein the tablet comprises sodium croscarmellose. 12. The method of claim 7, wherein the tablet comprises gelatin. 13. The method of claim 7, wherein the tablet comprises magnesium stearate. 14. The method of claim 7, wherein the tablet comprises hydroxypropylcellulose or hydroxypropylmethyl-cellulose. 15. The method of claim 7, wherein the tablet comprises polyvinyl polypyrrolidone. 16. The method of claim 1, further comprising administering to the human a second agent effective for the treatment of hyperuricemia associated with gout. 17. The method of claim 16, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, or a combination thereof. 18. The method of claim 16, wherein the second agent is allopurinol, febuxostat, FYX-051, or a combination thereof. 19. The method of claim 16, wherein the second agent is allopurinol. 20. The method of claim 16, wherein the second agent is febuxostat. 21. A method of treating hyperuricemia associated with gout in a human, the method comprising administering to the human a compound of formula (IV): ##STR00179## |
